The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2019 | MRD: venetoclax vs. BTK-inhibitors for CLL
Susan O’Brien
• 1 Jun 2019
Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses how MRD impacts the choice of different treatments for chronic lymphocytic leukemia (CLL), specifically mentioning venetoclax and BTK-inhibitors. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
